Urothelial Carcinoma Treatment Market Research Report – Forecast to 2030

Urothelial Carcinoma Treatment Market Research Report: By Types (Non-Invasive & Invasive Urothelial Carcinoma), by Treatment (Immunotherapy, Radiotherapy, Chemotherapy), by End-User (Hospital Pharmacy, Retail Pharmacy, Others) – Forecast Till 2030

ID: MRFR/Pharma/4983-HCR | February 2023 | Region: Global | 100 Pages         

Urothelial Carcinoma Treatment Market Speak to Analyst Request a Free Sample

Urothelial Carcinoma Treatment Market Scenario:


The Urothelial Carcinoma Treatment Market is anticipated to reach USD 3.2 Billion by 2030 at 19.10% CAGR during the forecast period 2022-2030.

Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract. Hence the market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the market during the forecast period.  

Various factors that can hamper the growth of the market are the presence of the generic drug in the market and the high cost of R&D investment for the development of a new drug for treatment.

Urothelial Carcinoma Treatment Market Segmentation

The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.

Urothelial Carcinoma Treatment Market Key players


  • GlaxoSmithKline plc

  • Genentech, Inc

  • Novartis AG

  • Dendreon

  • Merck KGaA

  • Eisai Co

  • Sanofi S.A

  • Bristol-Myers Squibb


Regional Market Summary  

Global Urothelial Carcinoma Treatment Market Share (%), by Region, 2017


Urothelial Carcinoma Treatment Market Share


Source: Centers for Disease Control and Prevention (CDC)


On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.


Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia-Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.


The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.


Global Urothelial Carcinoma Treatment Market, by Type



  • Non-invasive urothelial carcinoma treatment

  • Invasive urothelial carcinoma treatment


Global Urothelial Carcinoma Treatment Market, by Treatment



  • Immunotherapy

  • Radiotherapy

  • Chemotherapy


Global Urothelial Carcinoma Treatment Market, by End-User



  • Hospital pharmacy

  • Retail pharmacy

  • Others


Global Urothelial Carcinoma Treatment Market, by Region


Americas

  • North America

  • US

  • Canada

  • South America


Europe

  • Western Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific


Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   2022-2030: 19.10%
  Base Year   2021
  Forecast Period   2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Treatment, And End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb
  Key Market Opportunities   Investment in R&D activities to come up with new cancer treatment
  Key Market Drivers   Growing prevalence of cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Urothelial Carcinoma, also known as transitional cell carcinoma, is a cancer of the urinary bladder that can spread to other parts of the body.

Urothelial Carcinoma is expected to exhibit a strong 19.10% CAGR over the forecast period from 2022 to 2030.

Growing prevalence of cancer is the major driver for the market.

Americas hold the largest share in the global Urothelial Carcinoma Market.

Leading players in the Urothelial Carcinoma Market include Sanofi, Genentech, and Novartis, among others.